Inmune Bio, Inc. 8-K Filing

Ticker: INMB · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1711754

Inmune Bio, Inc. 8-K Filing Summary
FieldDetail
CompanyInmune Bio, Inc. (INMB)
Form Type8-K
Filed DateDec 8, 2025
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Inmune Bio, Inc. (ticker: INMB) to the SEC on Dec 8, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per share INMB The NASDAQ Stock Mar).

How long is this filing?

Inmune Bio, Inc.'s 8-K filing is 2 pages with approximately 563 words. Estimated reading time is 2 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 563 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-12-08 16:00:25

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share INMB The NASDAQ Stock Mar

Filing Documents

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On December 5, 2025, INmune Bio Inc. (the "Company") entered into Amendment No. 5 (the "Amendment") to the Rights Agreement, dated as of December 30, 2020, between the Company and VStock Transfer, LLC, as Rights Agent, as amended (the "Rights Agreement"). The Amendment extended the expiration of the Rights Agreement to December 31, 2026 and provides that such expiration date will automatically extend for successive one-year terms, unless the Company's Board of Directors determines not to extend the Rights Agreement. The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, which is attached hereto as Exhibit 4.1 and is incorporated herein by reference.

03 Material

Item 3.03 Material Modification to Rights of Security Holders The information set forth under "Item 1.01 Entry into a Material Definitive Agreement" of this Current Report on Form 8-K is incorporated into this

03 by reference

Item 3.03 by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits Number Description 4.1 Amendment No. 5 to Rights Agreement, dated as of December 5, 2025, between the Company and VStock Transfer LLC, as Rights Agent. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 8, 2025 INMUNE BIO INC. By: /s/ David Moss David Moss Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.